Literature DB >> 25425725

Intracranial hemorrhage detection over time using susceptibility-weighted magnetic resonance imaging.

Juliane Schelhorn1, Carolin Gramsch2, Cornelius Deuschl2, Harald H Quick3, Felix Nensa2, Christoph Moenninghoff2, Marc Schlamann2.   

Abstract

BACKGROUND: The reliable detection of intracranial hemorrhages is important, but just 1 year after the hemorrhage onset it might be missed using T2-weighted spin-echo and gradient-echo sequences. Susceptibility-weighted imaging (SWI) is a new magnetic resonance imaging sequence that is extremely sensitive in hemorrhage detection and that might improve the detection of hemorrhages over time.
PURPOSE: To investigate whether the detectability of intracranial blood and its degradation products is independent of the time span after intracranial hemorrhage using SWI.
MATERIAL AND METHODS: Sixty-six consecutive patients (28 men, 38 women) with definitely known time point of intracranial hemorrhage and available SWI sequence (1.5 or 3 T) were analyzed retrospectively. Twenty-one patients had a SWI follow-up. All SWI images were assessed by two radiologists in consensus regarding hemorrhage visibility using a 5-point scale. Statistical analysis was performed using Spearman's correlation test.
RESULTS: Median time interval between hemorrhage and first available SWI measurement was 819 days (range, 0 days to 13.2 years). Nine of 66 patients had an isolated subarachnoid hemorrhage (iSAH) and were therefore analyzed separately. In eight of these nine patients the hemorrhage could clearly be detected, the remaining one had minor iSAH. Spearman analysis showed no significant correlation between time span and visibility (P = 0.660). In the remaining 57 patients (no iSAH) the hemorrhage was always visible achieving at least 3/5 points on the 5-point scale, and Spearman's analysis revealed only a weak correlation between time span and visibility (r = 0.493, P < 0.001).
CONCLUSION: The detectability of blood and its degradation products using SWI is reliably possible over a long period after intracranial hemorrhage. © The Foundation Acta Radiologica 2014.

Entities:  

Keywords:  Intracranial hemorrhage; hemosiderin; magnetic resonance imaging (MRI); susceptibility-weighted imaging (SWI)

Mesh:

Year:  2014        PMID: 25425725     DOI: 10.1177/0284185114559958

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.990


  5 in total

Review 1.  Imaging of cerebrovascular disorders: precision medicine and the collaterome.

Authors:  David S Liebeskind; Edward Feldmann
Journal:  Ann N Y Acad Sci       Date:  2015-04-28       Impact factor: 5.691

2.  MRI follow-up after magnetic resonance-guided focused ultrasound for non-invasive thalamotomy: the neuroradiologist's perspective.

Authors:  Vera C Keil; Valeri Borger; Veronika Purrer; Simon F Groetz; Lukas Scheef; Henning Boecker; Hans H Schild; Christine Kindler; Angelika Schmitt; Laszlo Solymosi; Ullrich Wüllner; Claus C Pieper
Journal:  Neuroradiology       Date:  2020-05-03       Impact factor: 2.804

Review 3.  Pediatric Abusive Head Trauma: A Systematic Review.

Authors:  Aniello Maiese; Francesca Iannaccone; Andrea Scatena; Zoe Del Fante; Antonio Oliva; Paola Frati; Vittorio Fineschi
Journal:  Diagnostics (Basel)       Date:  2021-04-20

4.  Nigrosome 1 visibility at susceptibility weighted 7T MRI-A dependable diagnostic marker for Parkinson's disease or merely an inconsistent, age-dependent imaging finding?

Authors:  Carolin Gramsch; Iris Reuter; Oliver Kraff; Harald H Quick; Christian Tanislav; Florian Roessler; Cornelius Deuschl; Michael Forsting; Marc Schlamann
Journal:  PLoS One       Date:  2017-10-10       Impact factor: 3.240

5.  Traumatic shaking: The role of the triad in medical investigations of suspected traumatic shaking.

Authors:  Göran Elinder; Anders Eriksson; Boubou Hallberg; Niels Lynøe; Pia Maly Sundgren; Måns Rosén; Ingemar Engström; Björn-Erik Erlandsson
Journal:  Acta Paediatr       Date:  2018-09       Impact factor: 2.299

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.